Drugs / Iodine
Iodine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04344236 | Apr → May 2020 | COVID-19 | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT03688958 | Mar 2005 → Dec 2009 | breast cancer | Universidad Nacional Autonoma de Mexico | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01021007 | Oct → Nov 2007 | smooth surface dental caries | Colgate Palmolive | Completed | Mixed |
| Phase not applicable1 trial | ||||||
| — | NCT00247897 | Nov 2005 → Oct 2007 | skin disease caused by bacterial infection | University of British Columbia | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2/3 | NCT06220344 Comparator | Dec 2022 → Mar 2023 | skin infection | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT07758335 Comparator | Jul 2025 → Mar 2027 expected | ulcerative colitis | National Hepatology & Tropical Medicine Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT03412734 Comparator | May 2018 → Aug 2019 | — | TriHealth Inc. | Terminated | Met primary Stop: Enrollment |
| Phase 4 | NCT02018094 Comparator | Oct 2013 → Mar 2014 | skin infection | Hull University Teaching Hospitals NHS Trust | Completed | No outcome recorded |
| — | NCT06063941 Comparator | Oct 2023 → Apr 2024 | esophageal squamous cell carcinoma | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| — | NCT02929927 Background | Mar 2016 → Dec 2023 | dental radicular dysplasia | Fujian Medical University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iodine | “Subjects in the D group will have their skin prepared with a single-use 6mL-unit applicator that contains a sterile, crushable ampoule of iodine 0.7% with 74% isopropyl alcohol.” NCT00247897 ↗ |
| Known as | molecular iodine | “The trial investigates the effect of oral supplement of molecular iodine (I2) alone and in combination with 4 to 6 cycles of FEC/TE (5-fluorouracil, epirubicin,...” NCT03688958 ↗ |
| Known as | Povidone/Iodine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04344236 ↗ |
| Modality | Other / unclassified | “trace elements (zinc 15 mg, chromium 15 mcg, selenium 15 mcg, copper 1000 mcg, iodine 75 mcg, iron 30 mg, magnesium 2.5 mg, molybdenum 15 mcg)” NCT07758335 ↗ |
| Route | Oral | “oral supplement of molecular iodine (I2)” NCT03688958 ↗ |